Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. III. Polyvalent serum against three mucoid immunotypes potentiates phagocytosis of all (7) mucoid immunotypes
Affiliations
- PMID: 3149178
Item in Clipboard
Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. III. Polyvalent serum against three mucoid immunotypes potentiates phagocytosis of all (7) mucoid immunotypes
Arch Immunol Ther Exp (Warsz).
1988.
Abstract
Polyvalent serum against mucoid variants of immunotypes 1, 3 and 5, according to Fisher's scheme, was shown to stimulate immune response in phagocytic test of all mucoid immunotypes.
Similar articles
-
Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. I. Induction of homologous immunity by nonmucoid strains of P. aeruginosa.Arch Immunol Ther Exp (Warsz). 1988;36(2):177-84. Arch Immunol Ther Exp (Warsz). 1988. PMID: 2467637
-
Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. II. Induction of heterologous immunity by mucoid strains of P. aeruginosa.Arch Immunol Ther Exp (Warsz). 1988;36(2):185-93. Arch Immunol Ther Exp (Warsz). 1988. PMID: 3149177
-
Evaluation of polyvalent anti-Pseudomonas aeruginosa vaccine in phagocytic reaction.Arch Immunol Ther Exp (Warsz). 1990;38(3-4):291-7. Arch Immunol Ther Exp (Warsz). 1990. PMID: 2129384
-
Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.Behring Inst Mitt. 1997 Feb;(98):350-60. Behring Inst Mitt. 1997. PMID: 9382760 Review.
-
Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.Expert Rev Vaccines. 2005 Oct;4(5):645-56. doi: 10.1586/14760584.4.5.645. Expert Rev Vaccines. 2005. PMID: 16221066 Review.